Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed540ded24dcd4be2c7d104919bb284c |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
filingDate |
2009-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_291b8b01ee20180668213f1b86ae6548 |
publicationDate |
2010-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2010076033-A1 |
titleOfInvention |
Methods For Treating Hyperlipidemia with Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics |
abstract |
Methods for treating hyperlipidemia with intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, without causing drug-induced hepatotoxicity to a level which would require discontinuation of the therapy, whereby a majority of the nicotinic acid is release and metabolized in the individual within about 5 to about 9 hours. The present methods of treatment also contemplate administering the intermediate release nicotinic acid formulations composition according to a titrated dosage regimen to reduce flushing. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7998506-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005118257-A1 |
priorityDate |
1993-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |